This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Owlet (OWLT), Praxis Precision Medicines (PRAX) and Sarepta Therapeutics (SRPT)

Tipranks - Tipranks - Fri Jun 19, 6:54AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Owlet (OWLT), Praxis Precision Medicines (PRAX) and Sarepta Therapeutics (SRPT).

Claim 55% Off TipRanks

Owlet (OWLT)

Northland Securities analyst Owen Rickert maintained a Buy rating on Owlet today and set a price target of $13.00. The company’s shares closed last Wednesday at $4.66.

According to TipRanks.com, Rickert is a 2-star analyst with an average return of 0.6% and a 50.7% success rate. Rickert covers the NA sector, focusing on stocks such as Savers Value Village Inc., Life Time Group Holdings, and Barnes & Noble Education. ;'>

Currently, the analyst consensus on Owlet is a Strong Buy with an average price target of $13.33.

See the top stocks recommended by analysts >>

Praxis Precision Medicines (PRAX)

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Praxis Precision Medicines, with a price target of $1200.00. The company’s shares closed last Wednesday at $270.01.

According to TipRanks.com, Rahimi is a 5-star analyst with an average return of 28.3% and a 45.8% success rate. Rahimi covers the Healthcare sector, focusing on stocks such as First Tracks Biotherapeutics Inc, NewAmsterdam Pharma Company, and Crinetics Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Praxis Precision Medicines with a $613.56 average price target, implying a 136.8% upside from current levels. In a report released yesterday, RBC Capital also initiated coverage with a Buy rating on the stock with a $449.00 price target.

Sarepta Therapeutics (SRPT)

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Sarepta Therapeutics, with a price target of $19.00. The company’s shares closed last Wednesday at $16.96.

According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 11.0% and a 52.7% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, Aardvark Therapeutics, Inc., and MoonLake Immunotherapeutics. ;'>

Sarepta Therapeutics has an analyst consensus of Hold, with a price target consensus of $22.81, implying a 41.2% upside from current levels. In a report issued on June 3, TipRanks – PerPlexity also reiterated a Hold rating on the stock with a $18.50 price target.

Read More on OWLT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).